Deutsche Bank’s Matinas BioPharma MTNB Stock Holding History

Deutsche Bank’s Portfolio MTNB Stock Details MTNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-337	Closed	-$275K	–	5429
2019 Q1	$275K	Buy	+337	New	+$272K	﹤0.01%	3811
2018 Q4	–	Sell	-14	Closed	-$10K	–	5320
2018 Q3	$10K	Sell	14 -69	-83%	-$22.2K	﹤0.01%	5078
2018 Q2	$27K	Sell	83 -36	-30%	-$15.6K	﹤0.01%	4947
2018 Q1	$68K	Sell	119 -78	-40%	-$61.9K	﹤0.01%	4649
2017 Q4	$171K	Buy	197 +128	+186%	+$123K	﹤0.01%	4096
2017 Q3	$67K	Sell	69 -11	-14%	-$11K	﹤0.01%	4289
2017 Q2	$101K	Buy	+80	New	+$161K	﹤0.01%	4196

Other funds holding MTNB

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Vivo Capital Palo Alto, California $909M AUM 385.65% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $179B AUM 29.92% 1-Year Est. Return

Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Stonepine Capital Management Bend, Oregon $159M AUM 62.27% 1-Year Est. Return

Deutsche Bank's MTNB Position: Q2 2019 in Review

Deutsche Bank sold out of Matinas BioPharma (MTNB) in Q2 2019, closing a stake of 337 shares — an estimated $275K sold.

Deutsche Bank first reported a position in MTNB in Q2 2017 and held it in 7 quarters. The position peaked at $275K in Q1 2019. 45 funds tracked by Wall St. Rank hold MTNB as of Q2 2019.

Deutsche Bank reported no remaining Matinas BioPharma position as of Q2 2019 after selling out during the quarter.
Deutsche Bank sold 337 Matinas BioPharma shares in Q2 2019, an estimated $275K.
Deutsche Bank first reported a position in Matinas BioPharma in Q2 2017 and held it in 7 quarters.
Deutsche Bank's Matinas BioPharma position peaked at $275K in Q1 2019.
45 funds tracked by Wall St. Rank held Matinas BioPharma as of Q2 2019.

Based on Deutsche Bank's 13F filing for Q2 2019, filed 14 Aug 2019.